HONGISTO, Mari, Johan LASSUS, Tuukka TARVASMAKI, Jordi SANS-ROSELLO, Heli TOLPPANEN, Anu KATAJA, Toni JANTTI, Tuija SABELL, Marek BANASZEWSKI, Jose SILVA-CARDOSO, John PARISSIS, Raija JURKKO, Jindřich ŠPINAR, Maaret CASTREN, Alexandre MEBAZAA, Josep MASIP, Veli Pekka HARJOLA a CardShock Study Investigators And The Great NETWORK. Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock. EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE. LONDON: SAGE PUBLICATIONS LTD, 2022, roč. 11, č. 10, s. 731-738. ISSN 2048-8726. Dostupné z: https://dx.doi.org/10.1093/ehjacc/zuac096.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock
Autoři HONGISTO, Mari (garant), Johan LASSUS, Tuukka TARVASMAKI, Jordi SANS-ROSELLO, Heli TOLPPANEN, Anu KATAJA, Toni JANTTI, Tuija SABELL, Marek BANASZEWSKI, Jose SILVA-CARDOSO, John PARISSIS, Raija JURKKO, Jindřich ŠPINAR (203 Česká republika, domácí), Maaret CASTREN, Alexandre MEBAZAA, Josep MASIP, Veli Pekka HARJOLA a CardShock Study Investigators And The Great NETWORK.
Vydání EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, LONDON, SAGE PUBLICATIONS LTD, 2022, 2048-8726.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.100
Kód RIV RIV/00216224:14110/22:00128426
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1093/ehjacc/zuac096
UT WoS 000838679300001
Klíčová slova anglicky Cardiogenic shock; suPAR; Risk stratification; Biomarker
Štítky 14110115, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 31. 1. 2023 09:40.
Anotace
Aims Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker reflecting the level of immune activation. It has been shown to have prognostic value in acute coronary syndrome and heart failure as well as in critical illness. Considering the complex pathophysiology of cardiogenic shock (CS), we hypothesized suPAR might have prognostic properties in CS as well. The aim of this study was to assess the kinetics and prognostic utility of suPAR in CS. Methods and results SuPAR levels were determined in serial plasma samples (0-96 h) from 161 CS patients in the prospective, observational, multicentre CardShock study. Kinetics of suPAR, its association with 90-day mortality, and additional value in risk-stratification were investigated. The median suPAR-level at baseline was 4.4 [interquartile range (IQR) 3.2-6.6)] ng/mL. SuPAR levels above median were associated with underlying comorbidities, biomarkers reflecting renal and cardiac dysfunction, and higher 90-day mortality (49% vs. 31%; P = 0.02). Serial measurements showed that survivors had significantly lower suPAR levels at all time points compared with nonsurvivors. For risk stratification, suPAR at 12 h (suPAR(12h)) with a cut-off of 4.4 ng/mL was strongly associated with mortality independently of established risk factors in CS: OR 5.6 (95% CI 2.0-15.5); P = 0.001) for death by 90 days. Adding suPAR(12h) > 4.4 ng/mL to the CardShock risk score improved discrimination identifying high-risk patients originally categorized in the intermediate-risk category. Conclusion SuPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients.
VytisknoutZobrazeno: 21. 5. 2024 22:56